Recent technological advances in mass spectrometry permit reproducible and quantitative proteomic characterization of cohorts of cancer tissues. The combined proteomic and genomic analysis of cancer tissue from the same patient, termed proteogenomic analysis, is expected to provide complementary information, regarding the functional consequences of genomic aberrations at the protein level, and the identification of new therapeutic targets.
In this project, we are performing a proteogenomic analysis of a clinically well-defined cohort of gastric cancer patients, using a combination of whole exome sequencing, RNA-sequencing, and mass spectrometry-based proteomic profiling. Combining genomic and proteomic features, our analysis will provides a novel classification of GC associated with clinical outcome, and reveals opportunities to develop subtype-guided therapies in GC
Proteogenomic Analysis of Gastric Cancer (GC)
